Takeda』s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

首圖 OSAKA, Japan & CAMBRIDGE, Mass. — (BUSINESS WIRE) — Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for …


發佈留言